Cefuroxim MIP (Cefuroxime)

What Is Cefuroxim MIP and What Is It Used For?

Cefuroxim MIP belongs to the cephalosporin family of antibiotics, which are structurally and functionally related to penicillins. As a second-generation cephalosporin, cefuroxime offers improved activity against certain Gram-negative bacteria compared to first-generation agents, while retaining excellent coverage of Gram-positive organisms. The injectable formulation allows rapid achievement of therapeutic blood levels, making it particularly suitable for serious or systemic infections where oral therapy may be insufficient.

The active substance, cefuroxime (administered as cefuroxime sodium), exerts its bactericidal effect by binding to penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. This binding inhibits the transpeptidation step of peptidoglycan synthesis, which is essential for maintaining the structural integrity of the bacterial cell wall. Without a functional cell wall, bacteria undergo osmotic lysis and die. Cefuroxime is notably resistant to degradation by many common beta-lactamase enzymes, which gives it an advantage over first-generation cephalosporins and certain penicillins against enzyme-producing bacteria.

Cefuroxime demonstrates clinically relevant activity against a broad spectrum of organisms. Among Gram-positive bacteria, it is effective against Staphylococcus aureus (methicillin-susceptible strains), Streptococcus pneumoniae, Streptococcus pyogenes, and other streptococci. Its Gram-negative coverage includes Haemophilus influenzae (including beta-lactamase-producing strains), Moraxella catarrhalis, Escherichia coli, Klebsiella species, Proteus mirabilis, and Neisseria gonorrhoeae. It is also active against certain anaerobes. However, it is not effective against methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, Enterococcus species, or extended-spectrum beta-lactamase (ESBL)-producing organisms.

Cefuroxim MIP is indicated for the treatment of the following infections when caused by susceptible organisms:

• Lower respiratory tract infections – including community-acquired pneumonia, acute exacerbations of chronic bronchitis, and lung abscess
• Urinary tract infections – including pyelonephritis (kidney infection), complicated and uncomplicated cystitis
• Skin and soft tissue infections – including cellulitis, wound infections, and erysipelas
• Bone and joint infections – including osteomyelitis and septic arthritis
• Septicemia – bloodstream infections
• Meningitis – bacterial infection of the membranes surrounding the brain and spinal cord
• Gonorrhea – particularly uncomplicated urethral and cervical gonorrhea
• Surgical prophylaxis – prevention of infection during and after surgical procedures, including gastrointestinal, orthopedic, cardiovascular, and gynecological surgery
• Ear, nose and throat infections – including otitis media and sinusitis when parenteral therapy is warranted

According to the European Medicines Agency (EMA) guidelines and the British National Formulary (BNF), cefuroxime remains an important antibiotic for empirical treatment of community-acquired infections. The World Health Organization (WHO) includes cefuroxime on its Model List of Essential Medicines, underscoring its role as a critical therapeutic agent in global healthcare. In the WHO AWaRe classification system, cefuroxime is categorized as a "Watch" group antibiotic, meaning it should be used judiciously and its use monitored to prevent the emergence of resistance.

What Should You Know Before Taking Cefuroxim MIP?

Contraindications

Cefuroxim MIP is contraindicated in patients with a known history of severe hypersensitivity (anaphylaxis or severe skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis) to cefuroxime, to any other cephalosporin antibiotic, or to any of the excipients contained in the formulation. Due to the structural similarity between cephalosporins and penicillins, cross-reactivity may occur in patients with a history of immediate-type hypersensitivity reactions to penicillins. The estimated rate of cross-reactivity between penicillins and cephalosporins is approximately 1–2%, though the risk is higher in patients who have experienced anaphylaxis to penicillin.

Patients who have previously experienced a non-severe allergic reaction to penicillins (such as a mild rash) may still be candidates for cefuroxime treatment under close medical observation. However, patients who have experienced severe reactions such as anaphylaxis, angioedema, or severe urticaria to any beta-lactam antibiotic should not receive cefuroxime under any circumstances. Adequate emergency resuscitation equipment and trained personnel should always be available when administering cefuroxime, particularly to patients with a history of any type of drug allergy.

Warnings and Precautions

Several important warnings and precautions should be observed when using Cefuroxim MIP. Healthcare professionals should be aware of the following clinical considerations:

• Hypersensitivity reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibiotics. Before initiating treatment, careful inquiry should be made regarding previous hypersensitivity to cephalosporins, penicillins, or other allergens. If an allergic reaction occurs, the drug should be discontinued immediately and appropriate emergency treatment initiated, which may include epinephrine, corticosteroids, antihistamines, and airway management.
• Clostridioides difficile-associated diarrhea (CDAD): Antibiotic-associated colitis and pseudomembranous colitis have been reported with nearly all antibacterial agents, including cefuroxime, and may range in severity from mild diarrhea to life-threatening colitis. Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of Clostridioides difficile. C. difficile produces toxins A and B, which contribute to the development of CDAD. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
• Renal impairment: Cefuroxime is primarily eliminated by the kidneys through glomerular filtration and tubular secretion. In patients with significantly reduced renal function (creatinine clearance <20 mL/min), dosage adjustment is necessary to prevent drug accumulation and potential toxicity. Serum cefuroxime levels should be monitored in patients undergoing hemodialysis, as additional doses may be required after dialysis sessions.
• Superinfection: Prolonged use of cefuroxime may result in the overgrowth of non-susceptible organisms, including fungi such as Candida. If superinfection occurs during therapy, appropriate measures should be taken, including discontinuation of cefuroxime if necessary and initiation of targeted antifungal or antibacterial therapy.
• Interference with laboratory tests: Cefuroxime may cause a false-positive result in the Coombs test and in certain urine glucose tests that use copper-reduction methods (such as Benedict’s or Fehling’s reagent). Enzymatic glucose oxidase methods are not affected. Healthcare providers should be aware of this when interpreting laboratory results.
• Jarisch-Herxheimer reaction: A Jarisch-Herxheimer reaction has been observed following cefuroxime treatment of Lyme disease (borreliosis). This reaction results from the bactericidal activity of cefuroxime against the causative organism Borrelia burgdorferi and generally resolves spontaneously without specific treatment.
• Sodium content: Each 1500 mg vial contains approximately 3.6 mmol of sodium. This should be considered in patients on a sodium-restricted diet or those with conditions such as congestive heart failure where sodium intake must be carefully controlled.

Pregnancy and Breastfeeding

The safety of cefuroxime during pregnancy has been evaluated through both animal reproductive studies and human observational data. Animal studies have not demonstrated teratogenic effects at doses up to ten times the human therapeutic dose. Limited data from pregnant women, including registry data and case reports, indicate no increased risk of congenital malformations or adverse fetal outcomes. However, as with all medications during pregnancy, Cefuroxim MIP should only be used when the expected benefit to the mother outweighs any potential risk to the fetus, and this assessment should always be made by the treating physician.

Cefuroxime readily crosses the placental barrier, achieving therapeutic concentrations in fetal serum, amniotic fluid, and placental tissue. This pharmacokinetic property makes cefuroxime a useful choice for intrapartum antibiotic prophylaxis, such as in prevention of early-onset group B streptococcal disease, but also necessitates careful consideration of fetal exposure.

Cefuroxime is excreted in human breast milk in small quantities. At therapeutic doses, no clinically significant effects on the breastfed infant are anticipated, as the oral bioavailability of cefuroxime from breast milk is very low. However, the theoretical possibility of sensitization, diarrhea, or candidiasis in the nursing infant should be considered. If a nursing mother requires treatment with cefuroxime, the decision to continue breastfeeding should be made in consultation with the prescribing physician, weighing the benefits of breastfeeding against the potential risks of drug exposure to the infant.

How Does Cefuroxim MIP Interact with Other Drugs?

Drug interactions with cefuroxime are generally limited compared to many other antibiotics, but several clinically significant interactions should be considered. Healthcare professionals must review the patient’s complete medication list before initiating cefuroxime therapy, as concomitant use with certain drugs may require dosage adjustments, enhanced monitoring, or selection of an alternative antibiotic.

The mechanism of most cefuroxime interactions relates to its renal elimination pathway. Drugs that compete for tubular secretion or that independently affect renal function can alter cefuroxime’s pharmacokinetics. Additionally, cefuroxime’s effect on gut flora can influence the metabolism of certain concurrently administered medications, particularly those dependent on vitamin K synthesis by intestinal bacteria.

Major Interactions

Minor Interactions and Laboratory Interference

Cefuroxime has relatively few minor interactions. It does not inhibit or induce the hepatic cytochrome P450 enzyme system, meaning it has minimal impact on the metabolism of drugs processed through these pathways. This is a significant clinical advantage compared to some other antibiotic classes such as macrolides or fluoroquinolones. However, patients and healthcare providers should be aware of several laboratory test interferences:

• Coombs test: Cefuroxime may cause a false-positive direct Coombs test (direct antiglobulin test), which can be relevant for blood cross-matching, neonatal screening, and diagnosis of hemolytic anemia. A positive Coombs test has been reported in up to 3% of patients receiving cefuroxime.
• Urine glucose testing: Non-enzymatic copper-reduction methods (Benedict’s reagent, Fehling’s solution, Clinitest tablets) may give false-positive results for glucose in the urine. Glucose oxidase or hexokinase-based methods should be used instead for accurate results.
• Serum creatinine: The Jaffé reaction method for measuring serum creatinine may give transiently elevated readings during cefuroxime therapy, though this effect is generally small and clinically insignificant.

What Is the Correct Dosage of Cefuroxim MIP?

Cefuroxim MIP dosing is determined by the type and severity of infection, the susceptibility of the causative organism, and the patient’s age, weight, and renal function. As a parenteral formulation, it is administered exclusively by healthcare professionals in hospital or clinical settings. The powder must be reconstituted with an appropriate diluent (such as Water for Injections or 0.9% sodium chloride) prior to administration.

The drug can be administered via three routes: intramuscular (IM) injection into a large muscle mass (such as the gluteus maximus or lateral thigh), slow intravenous (IV) injection over 3–5 minutes directly into a vein or into the tubing of an existing IV line, or by intravenous infusion over 15–60 minutes. The choice of route depends on the clinical situation and the dose being administered. For doses exceeding 750 mg, the intravenous route is generally preferred to avoid the pain and tissue irritation associated with large-volume intramuscular injections.

Adults

Children

Pediatric dosing of cefuroxime is based on body weight. For most infections, the recommended dose is 30–60 mg/kg/day divided into three or four doses administered at equal intervals. For severe infections or meningitis, higher doses up to 100 mg/kg/day (maximum 6 g/day) may be required. The pharmacokinetics of cefuroxime in children are similar to those in adults when adjusted for body weight, with a half-life of approximately 1–2 hours in children with normal renal function.

Elderly

No specific dose adjustment is required for elderly patients with normal renal function. However, renal function naturally declines with age, and elderly patients are more likely to have impaired creatinine clearance even when serum creatinine levels appear within normal limits. Dosage should be adjusted based on estimated creatinine clearance using the Cockcroft-Gault formula or CKD-EPI equation, rather than serum creatinine alone, as serum creatinine may not accurately reflect renal function in elderly patients with reduced muscle mass.

Missed Dose

Since Cefuroxim MIP is administered by healthcare professionals in a clinical setting, the risk of missed doses is low. If a dose is inadvertently missed, it should be administered as soon as possible, and the regular dosing schedule should then be resumed. The interval between doses should not be significantly shortened to compensate for a missed dose, as this may increase the risk of adverse effects without providing additional therapeutic benefit. If a dose is missed by more than half the dosing interval, the missed dose may be skipped and the next scheduled dose administered at the regular time. Maintaining consistent drug levels is important for optimal bactericidal activity and to minimize the risk of resistance development.

Overdose

Overdosage of cefuroxime can lead to neurological complications including encephalopathy, seizures, and decreased consciousness, particularly in patients with impaired renal function who are unable to adequately excrete the drug. Overdose symptoms may also include severe nausea, vomiting, and diarrhea. Serum levels of cefuroxime can be reduced by hemodialysis and peritoneal dialysis. Treatment of overdose is primarily supportive, with maintenance of adequate hydration, monitoring of renal function, and management of seizures with appropriate anticonvulsant therapy. There is no specific antidote for cefuroxime overdose.

What Are the Side Effects of Cefuroxim MIP?

Like all medicines, Cefuroxim MIP can cause side effects, although not everybody gets them. The frequency and severity of adverse reactions depend on the dose, duration of treatment, route of administration, and individual patient factors including renal function, concurrent medications, and history of drug allergies. Most side effects associated with cefuroxime are mild to moderate in severity and resolve spontaneously after discontinuation of treatment.

Side effects are classified according to their frequency of occurrence based on clinical trial data and post-marketing surveillance reports from regulatory agencies worldwide. The following classification system is used, consistent with international pharmacovigilance conventions established by the Council for International Organizations of Medical Sciences (CIOMS) and adopted by the European Medicines Agency (EMA):

Patients should inform their healthcare team immediately if they experience any signs of a serious allergic reaction, including difficulty breathing, swelling of the face, lips, tongue, or throat, widespread rash with blistering, or signs of severe skin reactions such as skin peeling. Prolonged or bloody diarrhea occurring during or up to several weeks after treatment may indicate Clostridioides difficile infection and requires prompt medical evaluation. Anti-motility agents such as loperamide should not be used in this situation.

Injection site reactions are the most commonly reported adverse events and can be minimized through several strategies: rotating injection sites for IM administration, using deep IM injection technique into large muscle groups, administering IV injections slowly over 3–5 minutes, and using dilute solutions administered through large veins for IV infusion. Thrombophlebitis risk is reduced by administering the infusion over 15–60 minutes rather than as a rapid bolus injection, and by using alternating infusion sites.

How Should You Store Cefuroxim MIP?

Proper storage of Cefuroxim MIP is essential to maintain the drug’s potency, sterility, and safety. As a powder for injection/infusion, the product has specific storage requirements both before and after reconstitution that must be strictly followed by pharmacy and nursing staff.

Unopened vials: Store at or below 25°C (77°F). Keep the vials in the original outer carton to protect from light. Do not freeze. The product should be stored out of the reach and sight of children. Check the expiry date printed on the vial label and outer carton before use, and do not use the medicine after the expiry date. The expiry date refers to the last day of that month.

After reconstitution: Cefuroxime solutions may develop a pale yellow to amber color after reconstitution, which is normal and does not indicate loss of potency or degradation. However, darkly colored, turbid, or particulate-containing solutions should not be used. The reconstituted solution should always be inspected visually for particulate matter and discoloration prior to administration.

• Room temperature (15–25°C): Use within 8 hours of reconstitution.
• Refrigerated (2–8°C): Use within 24 hours of reconstitution.
• Do not freeze the reconstituted solution, as freezing may cause degradation of the active ingredient.
• Reconstituted solutions should be used as promptly as possible; any unused portion should be discarded appropriately.

From a chemical and physical in-use stability standpoint, the reconstituted solution is stable for the periods indicated above when stored under the specified conditions. However, from a microbiological perspective, the product should ideally be used immediately after reconstitution to minimize the risk of microbial contamination. If not used immediately, the in-use storage times and conditions are the responsibility of the user and would normally not exceed the times stated above, unless reconstitution has taken place in controlled and validated aseptic conditions.

What Does Cefuroxim MIP Contain?

Cefuroxim MIP is a relatively simple pharmaceutical formulation, consisting primarily of the active ingredient in its sodium salt form with no additional excipients. Understanding the composition is important for patients and healthcare professionals, particularly for those with sodium-restricted diets or known drug sensitivities.

Active Ingredient

Each vial contains cefuroxime sodium equivalent to 1500 mg of cefuroxime. Cefuroxime sodium is a white to slightly yellowish powder that is freely soluble in water. The molecular formula is C₁₆H₁₅N₄NaO₈S, and the molecular weight is approximately 446.4 g/mol for the sodium salt form. Cefuroxime belongs to the class of beta-lactam antibiotics, specifically the second-generation cephalosporins, characterized by the presence of a cephem ring structure with a methoxyimino group that confers stability against certain beta-lactamase enzymes produced by resistant bacteria.

Sodium Content

Each 1500 mg vial contains approximately 3.6 mmol (approximately 82.8 mg) of sodium. This should be taken into consideration in patients on a controlled sodium diet, patients with heart failure, or patients with conditions requiring sodium restriction such as hepatic cirrhosis with ascites or severe hypertension. When multiple doses are administered daily (e.g., 1500 mg three times daily), the cumulative sodium load can reach approximately 10.8 mmol (248.4 mg) per day, which may be clinically relevant in sodium-sensitive patients.

Reconstitution and Compatibility

Cefuroxim MIP powder must be reconstituted with a suitable diluent before administration. Compatible diluents include:

• Water for Injections (most commonly used)
• 0.9% Sodium Chloride solution (normal saline)
• 5% Dextrose (Glucose) solution
• 0.18% Sodium Chloride and 4% Dextrose solution
• Ringer’s lactate solution (Hartmann’s solution)

For intramuscular injection, the 1500 mg vial is typically reconstituted with 6 mL of Water for Injections to produce a suspension. For intravenous injection, the 1500 mg vial may be dissolved in at least 15 mL of Water for Injections to produce a clear solution. For intravenous infusion, the reconstituted solution may be further diluted with 50–100 mL of a compatible IV fluid. The powder should dissolve within approximately 1–2 minutes with gentle shaking or swirling; vigorous shaking should be avoided to prevent foaming.

The appearance of the product before reconstitution is a white to off-white powder or crystalline powder. After reconstitution, the solution is clear to slightly opalescent and ranges from colorless to pale yellow. A slight yellow color is normal and does not affect the product’s efficacy or safety. Solutions that are deeply colored, cloudy, or contain visible particles should not be administered.